Symptoms in aspartylglucosaminuria arise due to the deficiency of the enzyme aspartylglucosaminidase (AGA), an essential component in the process of oligosaccharide degradation [1]. Consequently, accumulation of oligosaccharides (specifically glycoasparagine) in various body tissues, primarly the central nervous system occurs, which is why mental retardation, developing in the first several years of life, is the most prominent clinical feature [2] [3]. The diagnosis is most frequently made between 5-6 years of age [2]. The decline of mental functions is progresses slowly throughout puberty and early adulthood, with rapid deterioration after 30 years of age and life expectancy is usually below 45 years of age [4] [5]. Progression seems to be slower in females, and due to the founder effect, this autosomal recessive condition is almost exclusively seen in the Finnish population [2] [5] [6]. An increased head circumference that shrinks with age (due to slow decay of brain cells) and a growth spurt during infancy are two most common accompanying signs, whereas the appearance of hernias, recurrent respiratory infections, delayed speech and cognitive development, gingival hyperplasia, and facial coarsening is reported as well [2] [4] [7]. Additional musculoskeletal (thickening of the ribs and skull, lordosis, vertebral dysplasia, contractures in fingers and elbows, a knock knee, muscle atrophy and hypotonia) and cutaneous (angiokeratomas, erythema and seborrheic dermatitis on the face) signs may be encountered, while many patients experience psychotic symptoms, restlessness, confusion and other psychiatric manifestations [2] [3] [4] [5]. Moreover, hepatosplenomegaly, cardiomyopathy, and macroorchidism, but also epilepsy and abnormal paroxysmal motor events during sleep can comprise the clinical presentation of aspartylglucosaminuria [2] [7]. In approximately 7% of cases, joint involvement is observed, mainly in the form of chronic arthritis [5].

A detailed patient history is the first and fundamental step for the diagnosis of aspartylglucosaminuria. Although pregnancy, perinatal period and early infancy are uneventful [2], the onset of mental retardation and accompanying facial, skeletal or other notable features in individuals of Finnish ancestry must prompt the physician to exclude this lysosomal storage disease as a possible cause [6]. More importantly, a complete family history may reveal similar findings in siblings or close relatives (due to the autosomal recessive pattern of inheritance), while consanguineous marriages are also an important risk factor [2] [4]. After a detailed physical examination and confirmation of central nervous system complaints, magnetic resonance imaging (MRI) of the endocranium, a procedure that solidifies its importance when it comes to the diagnosis of aspartylglucosaminuria, is recommended, and will show hyperintensity of white matter and hypointensity of the thalamus on T2-weighed images, as well as brain atrophy [2] [8]. On the other hand, laboratory investigations in the form of urine and serum testing is a more specific diagnostic method, comprised of detection of oligosaccharides and subsequent molecular analysis that will determine the activity of glycosylasparaginase, an enzyme necessary for their degradation [2] [4]. Finally, genetic testing to confirm mutations in the aspartylglucosaminidase (AGA) gene on chromosome 4q32-q33.1 is performed, and in the setting of a known mutation in one or both parents, a prenatal diagnosis from chorionic villus or amniotic fluid samples can be achieved [2] [4].

Currently, there is no cure for AGU, and treatment focuses on managing symptoms and improving quality of life. A multidisciplinary approach is often necessary, involving specialists such as neurologists, geneticists, and physical therapists. Supportive therapies may include speech and occupational therapy, special education programs, and medications to manage specific symptoms. Research is ongoing to explore potential treatments, including enzyme replacement therapy and gene therapy.

The prognosis for individuals with AGU varies depending on the severity of the condition and the effectiveness of symptom management. While the disease is progressive, early intervention and supportive care can help improve quality of life and functional abilities. Life expectancy may be reduced, but many individuals with AGU live into adulthood. Ongoing research aims to develop more effective treatments that could improve outcomes.

AGU is caused by mutations in the AGA gene, which provides instructions for producing the enzyme aspartylglucosaminidase. This enzyme is crucial for breaking down glycoproteins in the lysosomes, the cell's recycling centers. Mutations in the AGA gene lead to a deficiency or absence of the enzyme, resulting in the accumulation of glycoasparagines and the symptoms of AGU. The condition is inherited in an autosomal recessive pattern, meaning both copies of the gene must be mutated for the disease to manifest.

AGU is a rare disorder, with a higher prevalence in certain populations, such as those of Finnish descent. In Finland, the incidence is estimated to be 1 in 18,500, while it is much rarer in other populations. The condition affects both males and females equally. Due to its rarity, AGU may be underdiagnosed or misdiagnosed, particularly in regions where it is less common.

In AGU, the lack of functional aspartylglucosaminidase enzyme leads to the accumulation of glycoasparagines in the lysosomes. This accumulation disrupts normal cellular function and contributes to the symptoms of the disease. The buildup of these substances particularly affects the brain and other tissues, leading to the neurological and physical manifestations of AGU. The exact mechanisms by which these accumulations cause specific symptoms are not fully understood.

As a genetic disorder, AGU cannot be prevented. However, genetic counseling can help at-risk couples understand their chances of having a child with AGU. Prenatal testing and carrier screening are available for families with a known history of the condition. These options can provide valuable information for family planning and early intervention strategies.

Aspartylglucosaminuria is a rare genetic disorder characterized by the accumulation of glycoasparagines due to a deficiency in the enzyme aspartylglucosaminidase. It presents with developmental delays, intellectual disability, and other physical symptoms. While there is no cure, supportive treatments can help manage symptoms and improve quality of life. The condition is inherited in an autosomal recessive pattern, and genetic counseling is recommended for affected families.

Aspartylglucosaminuria (AGU) is a rare condition that affects how the body breaks down certain proteins. It is caused by changes in a specific gene and is passed down in families. People with AGU may have learning difficulties, speech problems, and other physical symptoms. While there is no cure, treatments can help manage symptoms. If you have a family history of AGU, genetic counseling can provide important information about your risk and options.

1. Opladen T, Ebinger F, Zschocke J, et al. Aspartylglucosaminuria: unusual neonatal presentation in Qatari twins with a novel aspartylglucosaminidase gene mutation and 3 new cases in a Turkish family. J Child Neurol. 2014;29(1):36-42.
2. Arvio M, Mononen I. Aspartylglycosaminuria: a review. Orphanet J Rare Dis. 2016;11:162.
3. Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson J, Loscalzo J. eds. Harrison's Principles of Internal Medicine, 18e. New York, NY: McGraw-Hill; 2012.
4. Tokola AM, Åberg LE, Autti TH. Brain MRI findings in aspartylglucosaminuria. J Neuroradiol. 2015;42(6):345-357.
5. Arvio M, Laiho K, Kauppi M, et al. Carriers of the aspartylglucosaminuria genetic mutation and chronic arthritis. Ann Rheum Dis. 2002;61(2):180-181.
6. Porter RS, Kaplan JL. Merck Manual of Diagnosis and Therapy. 19th Edition. Merck Sharp & Dohme Corp. Whitehouse Station, N.J; 2011.
7. Ambrosetto G, Santucci M. Sleep-related hypermotor seizures in aspartylglucosaminuria: a case report. Epilepsia. 2009;50(6):1638-1640.
8. Sui L, Lakshminarasimhan D, Pande S, Guo H-C. Structural basis of a point mutation that causes the genetic disease Aspartylglucosaminuria. Structure. 2014;22(12):1855-1861.